Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO Details
-
Open Date
24 Aug 2026
-
Close Date
27 Aug 2026
- IPO Price Range
₹ 938 to ₹988
- IPO Size
₹ 1,757 Cr
Symbiotec Pharmalab IPO Timeline
Symbiotec Pharmalab IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 24-Aug-2026 | 0.00 | 0.44 | 0.51 | 0.35 |
Last Updated: 24 August 2026 12:53 PM by 5paisa
Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products for domestic and international markets. With over 30 years of experience, it has developed into a backward-integrated manufacturing platform. The company operates two industrial-scale API facilities and holds approvals from regulatory authorities including the US FDA, EU-GMP and Korea’s Ministry of Food and Drug Safety, supporting research-led and quality-focused manufacturing practices.
Established in: 2002
Managing Director: Anil Satwani
Peers:
| Metric | Symbiotec Pharmalab Limited | Concord Biotech Limited | Divi's Laboratories Limited | Cohance Lifesciences Limited |
|---|---|---|---|---|
| Face Value | 2 | 1 | 2 | 1 |
| Closing price on August 17, 2026 | - | 1513.40 | 8495 | 444.70 |
| Revenue from operations for Fiscal 2026 | 8691.49 | 10549 | 105600 | 22685.50 |
| EPS Basic | 19.10 | 24.78 | 96.75 | 4.69 |
| EPS Diluted | 19.00 | 24.78 | 96.75 | 4.68 |
| NAV | 184.69 | - | 631 | - |
| P/E | - | 61.07 | 87.80 | 95.02 |
| RONW (%) | 9.48 | 14 | 16.50 | 7 |
Symbiotec Pharmalab Objectives
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
2. General corporate purposes
Symbiotec Pharmalab IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹1,757 Cr |
| Offer For Sale | ₹150 Cr |
| Fresh Issue | ₹620Cr |
Symbiotec Pharmalab IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,070 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹1,96,980 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹9,56,760 |
Symbiotec Pharmalab IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 0.00 | 35,50,608 | 855 | 0.084 |
| Non-Institutional Buyers | 0.44 | 26,62,955 | 11,74,935 | 116.084 |
| bNII | 0.30 | 17,75,303 | 5,35,410 | 52.899 |
| sNII | 0.72 | 8,87,652 | 6,39,525 | 63.185 |
| Individual Investors (IND category bidding for 2 Lots) | 0.51 | 62,13,562 | 31,92,825 | 315.451 |
| Total** | 0.35 | 1,24,60,533 | 43,96,560 | 434.380 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY24 | FY25 | FY26 |
| Revenue | 716.25 | 751.55 | 869.15 |
| EBITDA | 177.04 | 206.11 | 231.97 |
| PAT | 100.06 | 96.79 | 109.90 |
| Particulars (In ₹ Crores) | FY24 | FY25 | FY26 |
| Total Assets | 1294.79 | 1579.65 | 1780.79 |
| Share Capital | 10.94 | 10.94 | 12.55 |
| Total Liabilities | 579.94 | 764.95 | 631.20 |
| Particulars (In ₹Crores.) | FY24 | FY25 | FY26 |
| Net Cash Generated From / (used in) Operating Activities | 187.50 | 47.26 | 174.59 |
| Net Cash Generated From / (used in) Investing Activities | -206.41 | -306.52 | -226.93 |
| Net Cash Generated From / (used in) Financing Activities | 21.85 | 278.16 | 35.99 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 2.94 | 18.90 | -16.35 |
Strengths
1. Over three decades of pharmaceutical manufacturing experience.
2. Backward-integrated platform supports greater operational control.
3. Global regulatory approvals strengthen manufacturing credibility significantly.
4. Diversified capabilities across APIs and nutritional ingredients.
Weaknesses
1. Manufacturing operations concentrated across limited production locations.
2. Regulatory compliance requires continuous investment and oversight.
3. Complex manufacturing processes increase operational execution requirements.
4. International operations expose business to currency fluctuations.
Opportunities
1. Growing global demand for specialised pharmaceutical APIs.
2. Biotechnology expansion can diversify future revenue streams.
3. CDMO services offer broader international growth opportunities.
4. Nutraceutical demand supports expansion into specialty ingredients.
Threats
1. Stringent global regulations may increase compliance costs.
2. Competitive API markets could pressure product pricing.
3. Supply disruptions may affect manufacturing continuity significantly.
4. Currency volatility could impact international business performance.
1. Established presence across specialised steroidal API segments.
2. Backward integration supports greater manufacturing process control.
3. Global regulatory approvals support regulated market access.
4. Research capabilities enable expansion across complex products.
India’s pharmaceutical industry is supported by expanding generic drug demand, growing exports and increasing emphasis on domestic API manufacturing. Industry revenue is expected to grow at around 10% CAGR between FY2025 and FY2030. Within this landscape, Symbiotec Pharmalab’s presence across corticosteroid and steroidal-hormone APIs, biotechnology, fermentation and CDMO services positions it to participate in opportunities arising from regulated markets, complex products and evolving pharmaceutical manufacturing requirements globally.
- Companies
- Type
- Opening On
-
Sumax Engineering Ltd
- SME
- 25th Aug
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Symbiotec Pharmalab opens from August 24, 2026 to August 27, 2026.
The size of Symbiotec Pharmalab is ₹1,757 Cr.
The price band of Symbiotec Pharmalab IPO is fixed at ₹938 to ₹988.
Once the Symbiotec Pharmalab IPO is officially open, one can simply follow the process to apply for the IPO:
To apply for Symbiotec Pharmalab IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Symbiotec Pharmalab IPO
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Symbiotec Pharmalab is of 15 shares and the investment required is ₹14,070.
The share allotment date of Symbiotec Pharmalab IPO is August 28, 2026
The Symbiotec Pharmalab IPO will likely be listed on September 1, 2026.
JM Financial Ltd is the book running lead managers for Symbiotec Pharmalab IPO.
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
2. General corporate purposes